Try our corporate solution for free!
(212) 419-8286

Bristol-Myers Squibb's top products based on revenue 2016-2019

Bristol-Myers Squibb is a multinational pharmaceutical company headquartered in New York City. As of 2019, their top products included Opdivo, a drug used in the treatment of certain cancers, and Eliquis, an anticoagulant. Those drugs generated 7.2 and nearly eight billion dollars in revenue for the company, respectively. Other top drugs for the company included Orencia, Sprycel and Yervoy, to name a few. BMS announced in April 2019 and completed in November 2019 the acquisition of Celgene, thus making one of the largest pharma mega deals in the last years.

Bristol-Myers Squibb’s company profile

Bristol-Myers Squibb (BMS) is a pharmaceutical company that produces pharmaceuticals and biologics in several therapeutic areas. BMS has experienced increasing revenues, especially among their prioritized brand areas. Despite increasing revenues, the company’s net income has remained variable over time.

The global oncology market

The global oncology market has grown significantly in recent years, with new therapies being added every year. Bristol-Myers Squibb (BMS) was ranked third among the top pharmaceutical companies based on their global oncology market share. Other top pharmaceutical companies include Roche and Celgene. The top oncology products world-wide based on market share include Keytruda, Revlimid, and Opdivo, which are marketed by Merck, BMS, and Celgene (now also BMS), respectively.

Bristol-Myers Squibb's top products based on revenue from 2016 to 2019

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% Discount until November 30th
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

February 2020



Survey time period

2016 to 2019

Supplementary notes

Figures before 2018 were quoted from previous annual reports.
* Some product revenues in 2019 were already impacted by the acquisition of Celgene (Revlimid, e.g.).

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Oncology"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.